Success Metrics

Clinical Success Rate
87.5%

Based on 7 completed trials

Completion Rate
88%(7/8)
Active Trials
0(0%)
Results Posted
86%(6 trials)
Terminated
1(11%)

Phase Distribution

Ph phase_2
6
67%
Ph phase_1
3
33%

Phase Distribution

3

Early Stage

6

Mid Stage

0

Late Stage

Phase Distribution9 total trials
Phase 1Safety & dosage
3(33.3%)
Phase 2Efficacy & side effects
6(66.7%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

77.8%

7 of 9 finished

Non-Completion Rate

22.2%

2 ended early

Currently Active

0

trials recruiting

Total Trials

9

all time

Status Distribution
Completed(7)
Terminated(2)

Detailed Status

Completed7
Withdrawn1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
9
Active
0
Success Rate
87.5%
Most Advanced
Phase 2

Trials by Phase

Phase 13 (33.3%)
Phase 26 (66.7%)

Trials by Status

withdrawn111%
completed778%
terminated111%

Recent Activity

0 active trials
Showing 5 of 9
completedphase_2

Preoperative Treatment With Cetuximab and/or IMC-A12

NCT00957853
completedphase_1

A Study of IMC-A12 in Participants With Tumors Who No Longer Respond to Treatment or For Whom No Treatment is Available

NCT00785538
completedphase_2

Study Using IMC-A12 (Cixutumumab) With or Without Cetuximab in Participants With Metastatic Colorectal Cancer Who Have Failed a Treatment Regimen That Consisted of a Prior Anti-EGFR Therapy

NCT00503685
completedphase_2

Phase II Study of IMC-A12 in Patients With Mesothelioma Who Have Been Previously Treated With Chemotherapy

NCT01160458
withdrawnphase_1

A Phase I Study of IMC-A12 in Combination With Temsirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors

NCT01182883
View all 9 trials

Clinical Trials (9)

Showing 9 of 9 trials
NCT00957853Phase 2

Preoperative Treatment With Cetuximab and/or IMC-A12

Completed
NCT00785538Phase 1

A Study of IMC-A12 in Participants With Tumors Who No Longer Respond to Treatment or For Whom No Treatment is Available

Completed
NCT00503685Phase 2

Study Using IMC-A12 (Cixutumumab) With or Without Cetuximab in Participants With Metastatic Colorectal Cancer Who Have Failed a Treatment Regimen That Consisted of a Prior Anti-EGFR Therapy

Completed
NCT01160458Phase 2

Phase II Study of IMC-A12 in Patients With Mesothelioma Who Have Been Previously Treated With Chemotherapy

Completed
NCT01182883Phase 1

A Phase I Study of IMC-A12 in Combination With Temsirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors

Withdrawn
NCT00769795Phase 2

Study of Effectiveness of IMC-A12 Antibody Combined With Hormone Therapy Prior to Surgery to Treat Prostate Cancer

Completed
NCT00683475Phase 2

A Study of IMC-A12 or Ramucirumab Plus Mitoxantrone and Prednisone in Prostate Cancer

Completed
NCT00778817Phase 2

IMC-A12 With Mitotane vs Mitotane Alone in Recurrent, Metastatic, or Primary ACC That Cannot Be Removed by Surgery

Terminated
NCT00785941Phase 1

A Study of IMC-A12 Every 2 Weeks in Patients With Tumors Who No Longer Respond to Treatment or No Treatment is Available

Completed

All 9 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
9